Dr. Garcia Advances Aqualung Therapeutics to Human Clinical Trials

SWEHSC member, University of Arizona pulmonologist, and CEO and founder of Aqualung Therapeutics, Joe G.N. "Skip" Garcia, MD, recently closed on a major investment that will help advance his new lung inflammation treatment to human clinical trials. The drug, a monoclonal antibody known as ALT-100, will work to reduce lung inflammation and poor health outcomes from various respiratory diseases. Click here to read the full Arizona Daily Star article about Dr. Garcia.